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Seventy-four patients with chronic stable mild angina, mild cor-
onary artery disease (83% had one- or two-vessel disease) and 
normal left ventricular function were studied to measure the 
response of treadmill exercise performance and painful and silent 
ischemia in the ambulatory setting to randomly assigned treat-
ment with nifedipine or propranolol, and their combination; 
titration to maximal tolerated dosages was performed in double-
blind manner. 
At 3 months both nifedipine and propranolol reduced the 
weekly angina rate (p < 0.05); during treadmill exercise testing, 
increases (p < 0.05) were noted in time to angina and total 
exercise time and decreases in maximal ST depression at the end 
of exercise. There were no differences between the responses to 
nifedipine and propranolol and no significant additional changes 
were seen after another 3 months of therapy. The combination of 
nifedipine and propranolol reduced the number of patients with 
angina on exercise treadmill testing from 64% to 38% (p < 0.05). 
The efficacy of beta-adrenergic blocking agents, calcium 
channel blocking agents and their combination in the treat-
ment of patients with chronic stable angina pectoris is well 
established. Reduction of anginal symptoms and nitroglyc-
erin consumption during daily activity has been docu-
mented, as have improved performance on exercise testing 
and reduced ST segment depression on ambulatory electro-
cardiographic (ECG) monitoring (1-23). However, the stud-
ies of nifedipine combined with a beta-blocker have predom-
inantly involved patients with severe angina (6-18) and 
short-term observations of efficacy ranging from immediate 
responses to responses after 6 weeks of oral therapy with an 
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During ambulatory electrocardiographic monitoring before 
treatment, there were 1.4 ± 2.4 (mean ± SD) episodes/24 h of 
painful ischemia and a very low silent ischemia frequency: mean 
1.1 ± 2. 7 episodes/24 h, mean duration 16 ± 25 min/24 h. 
Treatment with propranolol and nifedipine resulted in reduction 
of episodes and duration of painful and painless ischemia; approx-
imately 77% of patients were free of all ischemic episodes. 
It is concluded that patients with chronic stable mild angina 
have a low incidence of silent ischemia. Nifedipine or propranolol 
alone, titrated to individualized maximally tolerated dosages, are 
equally effective in long-term control of painful and painless 
ischemia, anginal episodes and exercise-induced ischemia. Com-
bination therapy further reduced only exercise-induced angina 
and maximal exercise-induced ST depression. 
(JAm Coli Cardiol1992;19:409-17) 
occasional longer study of 8 to 15 weeks (8,14,18). Many 
patients with such severe angina now undergo some form of 
myocardial revascularization (24). 
The efficacy of pharmacologic agents in the long-term 
treatment of milder angina has not been clearly documented. 
Moreover, only a few studies of long-term efficacy of medical 
treatment of angina, especially with regimens involving com-
bination therapy, have been of sufficient duration to resemble 
actual clinical usage. In addition, studies are lacking on the 
optimal dosage and sequence of administration of these medi-
cations in combination. Although the many fixed dose studies 
have shown these agents to be effective in reducing ischemia, 
there is no documentation of their efficacy in treating patients 
with milder symptoms at individually titrated dosages either 
alone or in combination over a long term, as is common in 
clinical practice. Because more information in these areas is 
needed (25), these factors were considered in the design of this 
study, which was initiated in 1984 to evaluate the long-term 
response of symptoms and signs of ischemia in patients with 
chronic mild angina to treatment with nifedipine, propranolol 
and their combination. 
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Figure 1. Protocol design. After fulfilling entry 
criteria, patients discontinued use of all prophy-
lactic antianginal medications and took only sub-
lingual (S.L.) nitroglycerin (NTG) for 2 weeks 
(phase 1). After exercise treadmill testing (ETT), 
ambulatory electrocardiographic monitoring and 
review of the angina diary, patients were ran-
domly assigned to 3 months of treatment with 
either nifedipine or propranolol (phase 11). The 
measurements were repeated and the patients 
randomized to either continued treatment with 
the same drug or treatment with both drugs for 
another 3 months (phase Ill), after which the 
measurements were repeated. All drug titrations 
were performed in double-blind fashion and all 
patients underwent a second titration at the start 
of phase Ill. 
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Methods 
Patient selection. The study was performed at the Los 
Angeles County and University of Southern California Med-
ical Center; patient enrollment was begun in April 1984 and 
ended in November 1987. Patients were recruited from 
among those being evaluated for exertional angina. They 
were selected on the basis of 1) a history of chronic stable 
angina that was mild enough for them to tolerate a 2-week 
(control) period with only sublingual nitroglycerin and with 
no prophylactic antianginal medications. Angina was defined 
as the presence of a dull, pressurelike pain or discomfort in 
the precordium that was reproducibly brought on by exer-
tion or emotional upset. The patients had to have at least 
three episodes of angina/week and <50% variability in the 
weekly angina frequency for the 2 months before enrollment 
in the study. 2) Documented coronary artery disease. All but 
two patients had coronary arteriograms that demonstrated 
;:::70% stenosis in at least one major coronary artery. The 
other two patients had a well documented myocardial infarc-
tion (by history of pain, classic ECG changes and serum 
enzyme determinations) and a positive exercise treadmill 
test for myocardial ischemia. Patients were not enrolled if 
they had a myocardial infarction or coronary revasculariza-
tion procedure within the previous 3 months or if they had 
insulin-requiring diabetes, bronchospastic lung disease or 
other diseases with symptoms that could be confused with 
angina pectoris. Patients were also excluded if they had a left 
bundle branch block, left ventricular hypertrophy, digoxin 
therapy, treatment with antiarrhythmic agents or any condi-
tion or medication that would interfere with interpretation of 
ST segment changes on the exercise ECG. 
The study protocol was approved by the Institutional 
Review Board and informed written consent was obtained 
from all patients who participated in this study. 
Drug administration. During the 2-week control period 
(phase I), patients received only sublingual nitroglycerin, 
0.4 mg. The angina diaries were reviewed and symptom-
limited treadmill exercise testing and 24-h ambulatory ECG 
monitoring were performed. The patients were then random-
ized to treatment with either nifedipine or propranolol at the 
beginning of phase 11 (Fig. 1). Beginning with 10 mg of 
nifedipine or 20 mg of propranolol, titration to the maximal 
tolerated dose of medication was performed in double-blind 
fashion; each patient received two preparations at all times, 
one of which was a placebo during phase 11. At each titration 
visit, blood pressure and heart rate were measured just 
before medication and at 15-min intervals for 1 h. If the dose 
was tolerated without excessive symptoms, change in blood 
pressure (>20 mm Hg decrease) or heart rate (to <50 
beats/min), the patient was instructed to continue to take 
that dose four times a day. The dose was increased at 
intervals of 3 to 4 days, as tolerated, to a maximum of 30 mg 
of nifedipine (120 mg/day) or 80 mg of propranolol 
(320 mg/day). Pill counts were used to evaluate compliance 
with the prescribed medications and at least 85% compliance 
was required for continued participation in the study. 
After 3 months of treatment, each patient was again 
randomized to either continuation of the same single drug 
plus placebo or to substitution of the other drug for the 
placebo at the beginning of phase Ill (Fig. 1). In all patients, 
dose titration to the maximal tolerated dose was again 
performed in double-blind fashion at the start of phase Ill; 
neither the investigators nor the patient knew whether the 
placebo from phase 11 was being retitrated or whether the 
other active drug had been substituted for the placebo. 
Angina diaries. Each patient was given a pocket-sized 
diary at the start of the study and was instructed to record 
the time of each anginal episode and the severity of the 
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episode by checking a box for mild, moderate or severe 
intensity. Patients were also asked to note the number of 
nitroglycerin tablets taken, if any, for each episode. 
Ambulatory ECG monitoring. Each patient had a 24-h 
ambulatory (ECG) recording at the end of phase I (control 
period), phase 11 and phase Ill. Patients were encouraged to 
continue their normal daily activities while wearing the 
recorder. A model449B cassette recorder or model445 reel 
to reel recorder (both Del Mar Avionics) was applied and 
standard lead V 5 and an inferior lead were recorded for 24 h; 
these are accurate in representing ST segment depression. 
Analysis of ST segment depression was performed on the 
Trendsetter 11 system (Del Mar A vionics) for the cassettes 
and the Innovator (Del Mar Avionics) for the reel to reel 
tapes. The ST sample time was set to 60 ms after the J point 
with manual adjustment on the Innovator for each recording 
so that the computer measurement corresponded to the true 
level of ST depression at 0.08 s after the J point on the full 
disclosure printout of the ECG. Each episode of ST segment 
depression was defined as ;:::: I mm depression from baseline 
for a duration of at least I min and at least 1 min after 
recovery from a previous episode. Each episode was 
counted only after confirmation of the changes on a full 
disclosure printout of the ECG. Correlation between an 
episode of angina and an episode of ST depression was 
established by comparing the ST change with the time 
recorded in the angina diary or that indicated on the tape 
when the patient pressed the event marker on the tape 
recorder. A delay of up to 15 min between ST depression and 
patient notation was considered a symptomatic episode 
because patients indicated that amount of delay frequently 
elapsed between the onset of angina and their noting the time 
in the diary or remembering to push the event marker. 
Treadmill exercise testing. Each patient underwent symp-
tom-limited treadmill exercise testing at the end of phase I 
(control period), phase 11 and phase Ill. The baseline for ST 
segment analysis was established as the level of ST segment 
observed after 30 s of hyperventilation in the standing 
position on the treadmill within 1 min before the start of 
exercise. The Balke-Ware protocol was used and was 
modified by a 2-min initial stage at 2 mph and 0% grade. 
Patients exercised to one or more of the following end 
points: 1) "moderate" angina, defined as the degree of 
severity of angina at which the patient usually stopped 
activity; 2) >2 mm ST segment depression; 3) greater than 
moderate dyspnea; 4) fatigue; 5) decrease in systolic blood 
pressure> 10 mm Hg between any two measurements made 
at 1-min intervals; or 6) three or more consecutive premature 
ventricular complexes. 
Statistics. The data are expressed as mean values ± SD. 
For nonnormally distributed samples, the median value is 
also reported. Analysis of covariance was used to compare 
the means of normally distributed values. A nonparametric 
Wilcoxon paired signed-rank test was used to compare the 
means of nonnormally distributed values. The chi-square 
test was used to compare the distribution of patients accord-
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Table 1. Clinical Characteristics of74 Patients 
Age (yr) (mean ± SD) 
Male/female ratio 
NYHA angina class 
I 
11 
Ill 
History 
Prior MI 
CABG 
PICA 
Hypertension 
Coronary artery disease (~70% stenosis) 
I vessel 
2 vessel 
3 vessel 
L VEF (mean ± SD) 
54± 7 
49/25 
3 (4%) 
54 (73%) 
17 (23%) 
46 
lO 
I 
29 
29 (40%) 
31 (43%) 
12 (17%) 
0.62 ± 0.13 
CABG = coronary artery bypass grafting; L VEF = left ventricular 
ejection fraction; MI = myocardial infarction; NYHA = New York Heart 
Association; PICA = percutaneous transluminal coronary angioplasty. 
ing to the presence or absence of events. A p value :5 0.05 
was considered significant. 
Results 
Patient characteristics (Table 1). There were no signifi-
cant differences in the patient characteristics between the 
two groups. The patients' age averaged 54 years, left ven-
tricular systolic function was normal in all and most had one-
or two-vessel coronary disease. 
Despite the double-blind titration, approximately equiva-
lent daily dosages of nifedipine or propranolol were achieved 
in all groups except for the group that received a combina-
tion of nifedipine with propranolol subsequently added. This 
group tolerated a significantly lower dose of propranolol 
(Table 2). 
Angina diary (Table 3). There was a significant reduction 
in angina frequency with both nifedipine and propranolol at 
the end of 3 months of treatment, and this response was 
sustained at 6 months. Treatment with the combination of 
nifedipine and propranolol for 3 months did not result in a 
significant further reduction of angina frequency or nitro-
glycerin consumption. 
Table 2. Average Daily Dose of Study Medication 
Single drug 
At 3 months 
At 6 months 
Combination therapy 
Nifedipine with propranolol added 
Propranolol with nifedipine added 
Nifedipine 
(mg/day) 
79.3 ± 32.9 
65.2 ± 25.9 
79 ::!: 30.5 
84.9::!: 34.8 
Propranolol 
(mg/day) 
250.8 ± 82.6 
251.4 ± 70 
211 .1 ::!: 77.5* 
260::!: 83.8 
*p < 0.05 versus other propranolol doses. All values are mean values ::!: 
SD. 
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Table 3. Effect of Treatment on Angina Frequency and 
Nitroglycerin Use 
Phase I 
(control) 
Phase 11 
(3 months) 
Angina Frequency (episodes/week) 
Nifedipine 
Propranolol 
Nifedipine + propranolol 
Propranolol + nifedipine 
6.3 ± 4.3 
7.1 ± 5.8 
4.3 ± 6.4* 
3.2 ± 6.1* 
Nitroglycerin Use (tablets/week) 
Nifedipine 
Propranolol 
Nifedipine + propranolol 
Propranolol + nifedipine 
*p < 0.05 versus control. 
2 ± 5.7 
3.3 ± 3.1 
1.7 ± 5.7 
I ± 1.3 
Phase Ill 
(6 months) 
2.7 ± 5.6* 
2 ± 2.3* 
4.3 ± 7.9* 
1.3 ± 1.7* 
0.7 ± 1.6 
0.7 ± 1.2 
1.1 ± 2.2 
0.3 ± 0.4 
Treadmill exercise testing. Nifedipine and propranolol 
treatment for 3 months resulted in significant increases of 
time to onset of angina and total exercise time (Fig. 2); these 
responses were sustained after an additional 3 months of 
treatment. For patients who received nifedipine alone for 3 
months, time to onset of angina increased from 199 ± 96 to 
286 ± 139 s and this increase was accompanied by an 
increase in total exercise time from 342 ± 127 to 433 ± 133 s 
(p < 0.05 for both). At 6 months the subset of patients who 
received nifedipine alone maintained this improvement, with 
time of onset of angina 304 ± 108 and total exercise time of 
433 ± 132 s (both p < 0.05 vs. control). For propranolol 
alone, at 3 months, time to onset of angina increased from 
255 ± 139 to 342 ± 116 s and total exercise time from 314 ± 
157 to 421 ± 141 s (p < 0.05 for both). At 6 months the 
improvement was sustained at 346 ± 76 s for angina onset 
and 433 ± 159 s for total exercise time, (p < 0.05 vs. control 
for both). Nifedipine treatment did not alter the rate-
pressure product significantly despite the increase in exer-
cise times. However, after 3 months of treatment with 
propranolol there were significant decreases in rate-pressure 
product at the onset of angina (from 18,743 ± 5,570 to 13,494 
JACC Vol. 19, No. 2 
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± 3,229) and at the end of exercise (from 21,237 ± 4,933 to 
14,780 ± 3,277), that were also observed at 6 months (Fig. 
2). The number of patients who terminated their exercise test 
because of angina was significantly reduced by administra-
tion of nifedipine (from 30 to 22 of 36 patients; p = 0.04) but 
not by propranolol (from 26 to 24 of38 patients). The number 
of patients with > 1 mm ST segment depression at the end of 
exercise was not reduced significantly by either nifedipine, 
(from 22 to 17 of 36 patients) or propranolol (from 28 to 22 of 
38 patients). 
With the combination of nifedipine and propranolol nei-
ther the time to onset of angina nor the total exercise time 
was significantly different from the value obtained with 
either drug alone. Treatment with the combination of nifed-
ipine plus propranolol resulted in a time to angina onset of 
330 ± 155 sand a total exercise time of 435 ± 144 s, neither 
of which was significantly different from the value obtained 
with single drug treatment. The rate-pressure product at the 
end of exercise was significantly reduced by combination 
therapy. There was also a significant difference in the 
number of patients who stopped exercise because of angina 
(Fig. 3); combination therapy reduced the number of patients 
who stopped because of angina to 38% compared with 64% 
with a single drug therapy (p < 0.05). There were fewer 
patients (5 of 19) in the group in which propranolol was 
added to initial nifedipine therapy who had angina during 
exercise than in the group in which nifedipine was added to 
initial propranolol therapy (9 of 17) (p < 0.05). The group 
with propranolol added to nifedipine also had fewer patients 
who continued to have > 1 mm ST segment depression 
during exercise (3 of 19 vs. 6 of 17). 
Twenty-four hour ambulatory ECG (Tables 4 and 5). 
Technically satisfactory 24-h recordings were available in 52 
of the 74 patients. In the first 10 patients studied, our method 
of recording and analysis was still being developed and the 
studies were technically incomplete. In another 12 patients, 
one or another of the recordings was incomplete because of 
equipment problems or patient failure to keep the electrodes 
in place. The characteristics of the 52 patients with adequate 
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Figure 2. Exercise response to treat-
ment with either nifedipine alone or 
propranolol alone for 3 and 6 months. 
Increase in time to onset of angina and 
total exercise time resulted from either 
treatment and was sustained at 6 
months. Treatment with propranolol 
but not nifedipine reduced the rate-
pressure (double) product at peak ex-
ercise. CONT. = control period. 
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PATIENTS WITH ANGINA ON ETT 
PATIENTS WITH > I.Omm ST DEPRESSION 
ON ETT 
Figure 3. Response of angina and ST segment 
depression on exercise testing (ETT) to treat-
ment. The group initially treated with nifedipine 
with subsequent addition of propranolol had a 
significantly smaller proportion of patients with 
angina and s 1 mm of ST depression during 
exercise testing than did the groups receiving 
either drug alone or the group receiving nifedi-
pine after treatment with propranolol. MEDS = 
medications. 
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records before treatment and at both 3 and 6 months of 
treatment did not differ from those of the entire cohort. 
the total number of episodes/24 h of ischemia, painful 
episodes and silent episodes was a significant reduction (p < 
0.05 for all) (Table 4). In each category of ischemia, the 
distribution remained skewed with treatment. Silent isch-
emia without painful ischemia occurred in 12% of patients. 
Duration of ischemia/24 h also decreased in all categories 
(Table 5). 
In the control phase a mean of 2.6 ± 3.9 total 
episodes/24 h of ST depression were observed (Table 4); 
these were nearly evenly distributed between painful and 
silent (or painless) episodes of ischemia. Silent ischemia 
without painful episodes occurred in 19% of patients. The 
mean duration of total ischemia, painful ischemia and silent 
ischemia is indicated in Table 5. The distribution of episodes 
was not normal for either total, painful or silent episodes; the 
medians were 1, 0, and 0 episodes/24 h, respectively, and 
distribution of duration of ischemia was similarly skewed 
toward absence of ischemia with medians of 3.5, 0 and 
0 min/24 h for total, painful and silent ischemia, respectively. 
Of the 52 patients, 27 (52%) had no evidence of any isch-
emia, 33 (63%) had no painful ischemia and 29 (56%) had no 
silent ischemia on 24-h ambulatory ECG during the control 
phase. 
The effect of 3 months of treatment with a single drug on 
In response to treatment with nifedipine for 3 months, 
there was a decrease in the number of total, painful and 
silent episodes of ischemia; but the change was significant 
only for the reduction in the number of silent ischemic 
episodes. However, the decrease in the duration of ischemia 
was significant for each category (Table 5). Nifedipine in-
creased the number of patients who were entirely free of 
both painful and silent ischemia and increased the number of 
patients with fewer episodes (Fig. 4; Table 4). In all, 65% had 
no ischemia, 81% had no painful ischemia on 24-h ECG and 
77% had no silent ischemia. 
Treatment with propranolol for 3 months also resulted in 
Table 4. Episodes of Ischemia on Ambulatory ECG Monitoring (no./24 h) 
Total Episodes Painful Episodes Silent Episodes 
Patients Patients Patients 
Mean± SD With None Mean± SD With None Mean± SD With None 
Control period 2.6 ± 3.9 52% 1.4 ± 2.4 63% 1.1 ± 2.7 56% 
3 months 
Single drug 0.7 ± 1.4* 71%* 0.4 ± 1.2* 85%* 0.3 ± 1.4* 81%* 
Nifedipine 0.8 ± 1.4 65% 0.4 ± 1.1 81% 0.3 ± 0.8* 77%* 
Propranolol 0.6 ± 1.5 77% 0.3 ± 1.2* 88%* 0.3 ± 0.7* 85% 
6 months 
Single drug 0.7 ± 1.9* 77% 0.5 ± 1.8* 89% 0.2 ± 0.4 81% 
Combination 0.5 ± 1.4* 85% 0.04 ± 0.4*t 96% 0.5 ± 1.3* 85% 
*p < 0.05 versus control period; tp < 0.05 versus phase 11 (after 3 months of treatment with a single drug). 
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Table 5. Duration of Ischemia on Ambulatory ECG 
Monitoring (min/24 h) 
Total Painful 
Episodes Episodes 
Control period 33 ± 61 17 ± 51 
3 months 
Single drug 9 ± 22* 6 ± 20* 
Nifedipine 16 ± 35* 7 ± 20 
Propranolol 7 ± 21* 3 ± 14* 
6 months 
Single drug 9 ± 34* 7 ± 34* 
Combinaton 3 ± 10* 0.1 ± 0.6*t 
Silent 
Episodes 
16 ± 25 
3 ± 11* 
9 ± 31* 
4 ± 14* 
I± 3* 
3 ± 10* 
*p < 0.05 versus control period; tp < 0.05 versus phase 11 (3 months). All 
values are mean ± SD. 
a decrease in number of total, painful and silent episodes of 
ischemia (Table 4). The reduction in duration of all ischemia, 
as well as the duration of painful and painless ischemia, were 
significantly reduced by propranolol (Table 5). Propranolol 
treatment also increased the number of patients with no 
episodes of ischemia to 77% (Fig. 4; Table 4) and increased 
to 88% and 85%, respectively, the number who were free of 
painful or painless ischemia. 
At the end of 6 months in the study, patients who were 
receiving the combination of nifedipine and propranolol 
maintained a decreased number of episodes and a shorter 
duration of total, painful and silent ischemia (Fig. 4; Tables 
4 and 5) compared with observations in the control period. 
Continued treatment for the second 3 additional months with 
a single drug resulted in no further change in ischemia during 
ambulatory ECG monitoring. There was a small further 
reduction with combination treatment compared with treat-
ment with a single drug in total episodes of ischemia and 
painful ischemia. Silent ischemia without painful episodes 
occurred in 12% of patients. Painful ischemia was nearly 
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eliminated by combination treatment and the remaining 
ischemia was nearly all silent ischemia. At the end of 3 
months of treatment with the combination of nifedipine and 
propranolol, 22 (85%) of the 26 patients had no episodes of 
ischemia, 96% had no episodes of painful ischemia and 85% 
had no episodes of silent ischemia during the 24 h of 
ambulatory ECG monitoring. 
Cardiovascular events. During the 6-month study period, 
untoward cardiovascular events (death, nonfatal myocardial 
infarction, revascularization procedure) did not occur in any 
patient. 
Discussion 
Response to nifedipine and propranolol treatment. In this 
study, patients had a significant reduction in angina fre-
quency with either nifedipine or propranolol treatment for up 
to 6 months; the responses to therapy were quite constant 
over 6 months. These were predominantly patients with mild 
angina based on their New York Heart Association angina 
class; most had one- or two-vessel coronary disease and all 
had normal left ventricular systolic pump function. Although 
a frequency of angina of 6.3 to 7.1 episodes/week seems 
high, it was recorded during the 2nd week of a 2-week period 
when all prophylactic antianginal medications had been 
withdrawn. Performance during exercise testing was also 
improved by either nifedipine or propranolol treatment, with 
an increase in time to onset of angina and total exercise time. 
Combination therapy produced additional benefit only as 
measured by a reduction in the number of patients having 
angina and > 1 mm ST depression during exercise and a 
reduction in painful ischemia on ambulatory ECG monitor-
ing. Silent ischemia was not very common before treatment 
and it responded to . treatment with either nifedipine or 
propranolol alone and followed the same course as painful 
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ischemia. Although combination treatment was effective in 
reducing angina in the ambulatory setting, it was no more 
effective than a single drug in reducing silent ischemia. 
Comparison with previous studies. Previous comparisons 
of the efficacy of calcium-channel blockers and beta-
adrenergic blockers in the treatment of angina have evalu-
ated fixed dose therapy after a period of usually 1 to 6 weeks 
and occasionally as long as 3.5 months (1-23). The present 
study clearly demonstrates that a decrease in angina fre-
quency and an increase in both time to onset of angina and 
total exercise time resulted from treatment with either nifed-
ipine alone or propranolol alone for 3 months. It further 
shows that over a long term this benefit is sustained after 6 
months of treatment with either drug alone. 
However, our study differed from previous investigations 
of nifedipine combined with propranolol in that fixed doses 
were not used and the drugs in all patients were titrated to 
their maximally tolerated dose in a manner analogous to a 
clinical strategy aimed at angina elimination. To our knowl-
edge ours is the only efficacy study to include such a titration 
in a double-blind fashion in comparing nifedipine and pro-
pranolol and their combination. The paucity of data in this 
area has recently been noted (25). As expected, side effects 
were frequently observed and frequently precluded patients 
from achieving additional doses of medication. We also 
found that patients already receiving their maximally toler-
ated dose of nifedipine were generally not able to take as 
high a dose of propranolol as that taken by the other groups 
initially treated with propranolol. However, the nifedipine 
dose tolerated by those already receiving propranolol did not 
differ from the dose in patients who received nifedipine only. 
The deleterious effect of beta-blockers, especially in high 
doses when combined with verapamil (2), diltiazem (13) and 
nifedipine (16,20) in patients with left ventricular systolic 
dysfunction, is well described. However, in patients with 
stable angina and normal or mildly abnormal left ventricular 
function at rest, the addition of nifedipine to a beta-blocker 
may result in minimal or no change at rest and may prevent 
an exercise-induced decrease in ejection fraction (20,26). A 
prolongation of exercise duration has been observed in 
patients with angina when nifedipine is combined with 
propranolol (14) or metoprolol (17). In another study (8), in 
which results were similar to ours, an improvement in 
exercise tolerance in patients with severe angina was 
achieved when nifedipine was combined with a reduced dose 
of propranolol (one-half the dose required for full beta-
blockade) even though a lesser response was achieved when 
the combination included the full dose of propranolol. 
There appear to be no previous studies that have inves-
tigated the effects or significance of the dosing sequence 
when combination therapy is instituted. In our patients with 
essentially normal left ventricular systolic function and 
predominantly mild coronary disease (one- or two-vessel 
disease) who had propranolol added to nifedipine and whose 
dose of propranolol happened to be lower than that of the 
other group receiving combination therapy, a significant 
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further reduction in symptoms and signs of ischemia on 
exercise was also observed. It is possible that concomitant 
administration of a beta-blocker with nifedipine may influ-
ence the effective level of nifedipine and that patients 
already receiving a maximal tolerated dose of nifedipine may 
therefore tolerate addition of propranolol poorly. Such a 
drug interaction was recently reported in studies of the 
combination of nifedipine with diltiazem (27 ,28). 
Effect on hemodynamic variables. The hemodynamic al-
teration resulting from the combination of nifedipine and 
propranolol resembled that of propranolol alone. The rate-
pressure product at the onset of angina and at the end of 
exercise, as well as the change from rest for both of these 
variables, was less in those patients who received propran-
olol either alone or in combination. The sequence of drug 
dosing was not important with regard to rate-pressure prod-
uct because similar reduction was observed at peak exercise 
for either group treated with combination. A similar lack of 
effect on rate-pressure product was observed in a previous 
study (9) of patients with severe angina using fixed combi-
nations of 30 mg/day of nifedipine and 240/day of propranolol 
and 60 mg/day of nifedipine and 480 mg/day of propranolol 
although a reduction in induced ST depression was 
achieved. Our study using treadmill testing suggests that a 
similar effect occurs with variable individualized dosing. 
Effect on ischemia. Our study is also in agreement with 
previous studies in which the combination of nifedipine and 
propranolol resulted in improvement in markers of ischemia 
without a clear increase of exercise duration. The previous 
findings suggest that combination therapy using fixed dos-
ages of nifedipine and propranolol, the latter at doses pro-
ducing beta-blockade or at maximally tolerated dosages, 
may not be expected to increase exercise duration (7,11). 
However, results may be different when nifedipine is com-
bined with other beta-blockers (17 ,26). In our study, treat-
ment with maximally tolerated dosages of nifedipine and 
propranolol in combination resulted in further reduction of 
exercise-induced ST depression over that achieved by a 
single drug without an increase in exercise duration and also 
a reduction to near elimination of painful ST depression on 
ambulatory ECG monitoring. These results are encouraging 
for the clinical strategy of titrating medication dosage against 
symptoms. 
Role of 24-h ECG monitoring. The low level of pretreat-
ment ischemia detected on 24-h ambulatory ECG recordings 
in our study group is somewhat striking and has been 
observed (29-32) in other similar groups of patients with 
documented coronary disease who are asymptomatic or 
have mild angina. In particular, in a careful study (31) of 
ambulatory ECG monitoring in 42 patients, 79% of whom 
were in New York Heart Association class I or 11 (versus 
77% in our study), a mean of 6.3 ± 0.45 total episodes of 
ischemia/24 h with a mean total duration of 55.2 ± 7.1 min 
was observed. The slightly milder coronary disease of our 
study patients (83% with one- or two-vessel disease vs. 53% 
in that report) may be related to the slightly lower total 
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number of episodes (3 ± 4.3/24 h) and duration (41 ± 
69 min/24 h) of ischemia that we observed in our patients. 
These findings suggest that 1) a low frequency and duration 
of ischemia are related to both milder angina and lesser 
coronary disease; 2) in these patients, treatment with either 
nifedipine or propranolol controls silent ischemia when it 
controls painful ischemia; and 3) symptoms and severity of 
coronary disease are important factors to consider when 
comparing treatment responses of ischemia on ambulatory 
ECG studies. 
Silent ischemia. It has also been suggested that in patients 
with no symptoms but with significant coronary disease, a 
significant percentage may be expected to have no evidence 
of ischemia on 24 h or even 48 h of ambulatory ECG 
monitoring (29). In one study, up to 40% of patients (56% of 
untreated patients) with chronic stable angina, a positive 
exercise test and angiographically documented coronary 
artery disease had no episodes of ischemia on 48 h of 
monitoring (31). Of the 52 patients we studied with 24-h ECG 
monitoring, 52% had no evidence of ischemia during the 
control phase and this percent increased to 71% and 77% at 
the end of 3 and 6 months, respectively, of treatment with a 
single drug. In our patients, during treatment with either 
nifedipine or propranolol, we observed a reduction of silent 
ischemia to a very low level of 0.3 ± 0.8 and 0.3 ± 0. 7 
episodes/24 h, respectively; the change with each drug was 
statistically significant. We found no significant further re-
duction below this low level with the combination of nifed-
ipine and propranolol. The clinical significance of the persis-
tence of such a low level of silent ischemia on ambulatory 
ECG monitoring in treated patients remains to be estab-
lished. Furthermore, in our patients, silent ischemia oc-
curred independently of painful ischemia in only a small 
percent of patients: 19% of patients in the control phase and 
12% of patients after treatment with single drug or their 
combination. 
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